Overexpression of <i>FBLN1</i> can inhibit ferroptosis in LPS-induced ALI. by Yaping Yuan (2734228)

Subjects:

Schematic diagram of the mechanism by which curcumin ameliorates aging-induced TJ damage in SCs. by Chen Xue (699418)

Subjects:

D-gal-induced aging leads to reduced autophagy levels in SCs, which are restored by curcumin <i>in vitro.</i> by Chen Xue (699418)

Subjects:

Flowchart of the study participants. by Subeen Kim (11714313)

Subjects:

FBLN1 regulates ferroptosis by inhibiting TGF-β. by Yaping Yuan (2734228)

Subjects:

Characteristics of study participants in women according to frailty groups. by Subeen Kim (11714313)

Subjects:

Percentage of macronutrient intake relative to the acceptable macronutrient distribution range (AMDR) by frailty groups. by Subeen Kim (11714313)

Subjects:

Basic characteristics of the study participants by gender. by Subeen Kim (11714313)

Subjects:

Curcumin restores D-gal-induced SCs TJ injury through autophagy activation <i>in vitro.</i> by Chen Xue (699418)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

GLM models for predictors of monthly HIV costs. by Drew B. Cameron (10687420)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

A comparison of Paraquat concentrations ^a in various types of plants. by Vivat Keawdounglek (9710710)

Subjects:

Purposive Sampling of Traditional Lanna Restaurants. by Vivat Keawdounglek (9710710)

Subjects:

CONSORT of participants with OPV status. by Zahid Hasan Khan (6281396)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Laab Nuer^a. ^a Photographed by Vivat Keawdounglek. by Vivat Keawdounglek (9710710)

Subjects:

Association of <i>Shigella</i> infections with EE biomarker concentration over time. by Haley A. Liakakos (21445884)

Subjects:

Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects: